CFDE Data Portal | Search ANKRD36BP2

	Label	Description
	ANKRD36BP2 Gene (Entity type)	ENSG00000291127 - ankyrin repeat domain 36B pseudogene 2
	ANKRD36BP2 associations Collection (Entity type)	Associations for ANKRD36BP2_associations
	ANKRD36BP2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE178340 carfilzomib MM1.S 7 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172219 adenosine 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212312 FBXW7 knockout Reh 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE126463 pomalidomide MM1.S 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

ANKRD36BP2

ENSG00000291127 - ankyrin repeat domain 36B pseudogene 2

ANKRD36BP2 associations

Associations for ANKRD36BP2_associations

ANKRD36BP2 associations.tsv

A file from IDG as part of the Harmonizome project

GSE189035 inositol 2 v 4 human dn

A Gene Set from LINCS

GSE178340 carfilzomib MM1.S 7 v 9 human dn

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE172219 adenosine 2 v 1 human dn

A Gene Set from LINCS

GSE212312 FBXW7 knockout Reh 1 v 3 human up

A Gene Set from LINCS

GSE189035 inositol 2 v 7 human dn

A Gene Set from LINCS

GSE126463 pomalidomide MM1.S 4 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.